Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxotere + Tarceva in Older Men with HRPC
NCT00087035Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- May 2004
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in prostate cancer (PCa), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Objective Response Rate at 9 weeks and Duration of Response at 9 weeks. Started May 2004; status: completed.
02
Drugs
erlotinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00087035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087035.